US3037980A
(en)
*
|
1955-08-18 |
1962-06-05 |
Burroughs Wellcome Co |
Pyrrolopyrimidine vasodilators and method of making them
|
US3423398A
(en)
|
1965-05-10 |
1969-01-21 |
Pfizer & Co C |
Sangivamycin and derivatives thereof
|
US4140851A
(en)
|
1977-11-21 |
1979-02-20 |
The United States Of America As Represented By The Department Of Health, Education And Welfare |
Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides
|
JPS61189225A
(ja)
|
1985-02-15 |
1986-08-22 |
Airin:Kk |
抗アレルギ−剤
|
US4892865A
(en)
|
1987-12-01 |
1990-01-09 |
The Regents Of The University Of Michigan |
Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
|
US5726302A
(en)
|
1989-09-15 |
1998-03-10 |
Gensia Inc. |
Water soluble adenosine kinase inhibitors
|
US5763596A
(en)
|
1989-09-15 |
1998-06-09 |
Metabasis Therapeutics, Inc. |
C-4' modified adenosine kinase inhibitors
|
US5646128A
(en)
|
1989-09-15 |
1997-07-08 |
Gensia, Inc. |
Methods for treating adenosine kinase related conditions
|
US5674998A
(en)
|
1989-09-15 |
1997-10-07 |
Gensia Inc. |
C-4' modified adenosine kinase inhibitors
|
US5721356A
(en)
|
1989-09-15 |
1998-02-24 |
Gensia, Inc. |
Orally active adenosine kinase inhibitors
|
US5177064A
(en)
|
1990-07-13 |
1993-01-05 |
University Of Florida |
Targeted drug delivery via phosphonate derivatives
|
WO1992005200A1
(en)
|
1990-09-18 |
1992-04-02 |
Chemex Pharmaceuticals, Inc. |
Xenobiotic-antibody conjugates
|
WO1992017185A1
(en)
|
1991-03-29 |
1992-10-15 |
University Of Florida |
Targeted drug delivery via mixed phosphate derivatives
|
EP0530537B1
(en)
|
1991-08-12 |
1997-01-08 |
Takeda Chemical Industries, Ltd. |
Condensed pyrimidine derivatives, their production and use as antitumor agents
|
CA2129105A1
(en)
|
1992-02-12 |
1993-08-19 |
Michael J. Conrad |
Applications of fluorescent n-nucleosides and fluorescent structural analogs of n-nucleosides
|
US5502187A
(en)
|
1992-04-03 |
1996-03-26 |
The Upjohn Company |
Pharmaceutically active bicyclic-heterocyclic amines
|
GB9226879D0
(en)
|
1992-12-23 |
1993-02-17 |
Iaf Biochem Int |
Anti-viral compounds
|
JPH08506343A
(ja)
|
1993-02-03 |
1996-07-09 |
ジェンシア・インコーポレイテッド |
リキソフラノシル誘導体を含むアデノシンキナーゼ阻害物質
|
US5656745A
(en)
|
1993-09-17 |
1997-08-12 |
Gilead Sciences, Inc. |
Nucleotide analogs
|
US5798340A
(en)
|
1993-09-17 |
1998-08-25 |
Gilead Sciences, Inc. |
Nucleotide analogs
|
JPH07124252A
(ja)
|
1993-11-07 |
1995-05-16 |
Masashi Funayama |
化学療法剤を固定化した不溶性担体を用いた、負に帯電した 生理活性物質の吸着、分離および定量方法。
|
JPH10501532A
(ja)
|
1994-06-09 |
1998-02-10 |
スミスクライン・ビーチャム・コーポレイション |
エンドセリン受容体拮抗物質
|
US5554608A
(en)
|
1994-09-28 |
1996-09-10 |
Ahluwalia; Gurpreet S. |
Inhibition of hair growth
|
US6051578A
(en)
|
1996-02-12 |
2000-04-18 |
Pfizer Inc. |
Pyrazolopyrimidines for treatment of CNS disorders
|
DK0906329T3
(da)
|
1996-06-06 |
2004-02-09 |
Novartis Ag |
2'-Substituerede nukleosider og oligonukleotidderivater
|
US6468991B1
(en)
|
1997-01-16 |
2002-10-22 |
Cyclis Pharmaceuticals, Inc. |
Method of treating rhinoviral infections
|
US5955446A
(en)
|
1997-01-16 |
1999-09-21 |
Pentose Pharmaceuticals, Inc. |
Method of treating herpes infections with 2',5'-oligoadenylate-2',3'-cyclophosphate compounds
|
US6419934B1
(en)
*
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
TNF modulators for treating neurological disorders associated with viral infection
|
US6831069B2
(en)
|
1999-08-27 |
2004-12-14 |
Ribapharm Inc. |
Pyrrolo[2,3-d]pyrimidine nucleoside analogs
|
IL139197A0
(en)
|
1999-10-29 |
2001-11-25 |
Pfizer Prod Inc |
Use of corticotropin releasing factor antagonists and related compositions
|
CA2390821A1
(en)
|
1999-12-16 |
2001-06-21 |
Peter G. Klimko |
Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
|
US6455508B1
(en)
*
|
2000-02-15 |
2002-09-24 |
Kanda S. Ramasamy |
Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
|
KR100385281B1
(ko)
|
2000-02-15 |
2003-05-23 |
이승기 |
새로운 세포 주기 조절 인자 억제제
|
EP1149583A3
(en)
|
2000-04-13 |
2001-11-14 |
Pfizer Products Inc. |
Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
|
RS50236B
(sr)
|
2001-01-22 |
2009-07-15 |
Merck & Co.Inc., |
Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
|
WO2002069949A2
(en)
|
2001-03-06 |
2002-09-12 |
Prendergast Patrick T |
Combination therapy for reduction of toxycity of chemotherapeutic agents
|
US20020127593A1
(en)
|
2001-03-12 |
2002-09-12 |
Regents Of The University Of California |
Fluorescence assay for DNA modifying enzymes
|
AU2002329970A1
(en)
|
2001-09-04 |
2003-03-18 |
Isis Pharmaceuticals, Inc. |
Pyrrolo(2,3-d)pyrimidines for inhibiting rna-dependent rna viral polymerase
|
US7115741B2
(en)
|
2001-09-06 |
2006-10-03 |
Levy Daniel E |
4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
|
EP1438054A4
(en)
|
2001-09-28 |
2006-07-26 |
Idenix Cayman Ltd |
METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
|
US7361671B2
(en)
|
2001-11-15 |
2008-04-22 |
The Institute For Pharmaceutical Discovery, Inc. |
Substituted heteroarylalkanoic acids
|
WO2003051899A1
(en)
*
|
2001-12-17 |
2003-06-26 |
Ribapharm Inc. |
Deazapurine nucleoside libraries and compounds
|
CA2470521A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Micrologix Biotech Inc. |
Anti-viral 7-deaza l-nucleosides
|
WO2003062256A1
(en)
|
2002-01-17 |
2003-07-31 |
Ribapharm Inc. |
2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
|
US7323453B2
(en)
|
2002-02-13 |
2008-01-29 |
Merck & Co., Inc. |
Methods of inhibiting orthopoxvirus replication with nucleoside compounds
|
JP2003321472A
(ja)
|
2002-02-26 |
2003-11-11 |
Takeda Chem Ind Ltd |
Grk阻害剤
|
FR2836996A1
(fr)
|
2002-03-05 |
2003-09-12 |
Centre Nat Rech Scient |
PRECURSEURS DE TRACEURS IMMUNOLOGIQUES NON-PEPTIDIQUES COMPRENANT UN MOTIF TYROSYL-(X)n-LYSINE-(X)n-TYROSINE, PROCEDE DE PREPARATION ET LEURS APPLICATIONS
|
FR2836995B1
(fr)
|
2002-03-05 |
2006-09-22 |
Centre Nat Rech Scient |
Utilisation de derives de nucleosides comportant un groupement citrate pour la production d'anticorps ayant une affinite pour des nucleosides triphosphorylees et leurs applications
|
US6664266B2
(en)
|
2002-03-14 |
2003-12-16 |
Children's Medical Center Corporation |
Axon regeneration with PKC inhibitiors
|
AU2003241621A1
(en)
|
2002-05-24 |
2003-12-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
WO2004003138A2
(en)
|
2002-06-27 |
2004-01-08 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
JP2005533108A
(ja)
|
2002-07-16 |
2005-11-04 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体
|
US7094768B2
(en)
|
2002-09-30 |
2006-08-22 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis C virus infection
|
AU2003279797B2
(en)
|
2002-09-30 |
2009-10-22 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis C virus infection
|
KR101115210B1
(ko)
|
2002-10-31 |
2012-04-12 |
메타베이시스 테라퓨틱스, 인크. |
신규 시타라빈 모노포스페이트 전구약물
|
AU2003290596B2
(en)
|
2002-11-05 |
2011-05-12 |
Isis Pharmaceuticals, Inc. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
SI1576138T1
(sl)
*
|
2002-11-15 |
2017-07-31 |
Idenix Pharmaceuticals Llc |
2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo
|
US20040175384A1
(en)
|
2003-12-12 |
2004-09-09 |
Mohapatra Shyam S. |
Protein kinase C as a target for the treatment of respiratory syncytial virus
|
US7358262B2
(en)
|
2003-01-29 |
2008-04-15 |
Whitehead Institute For Biomedical Research |
Identification of genotype-selective anti-tumor agents
|
WO2007038613A2
(en)
|
2005-09-26 |
2007-04-05 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
US20040259934A1
(en)
|
2003-05-01 |
2004-12-23 |
Olsen David B. |
Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
|
WO2005020885A2
(en)
|
2003-05-21 |
2005-03-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
|
US7230007B2
(en)
|
2003-06-12 |
2007-06-12 |
Sanofi-Aventis Deutschland Gmbh |
Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
|
EP3279328A1
(en)
|
2003-11-14 |
2018-02-07 |
Children's Medical Center Corporation |
Self-cleaving ribozymes and uses thereof
|
US7351827B2
(en)
|
2003-11-21 |
2008-04-01 |
The University Of Connecticut |
Substituted oxetanes, method of making, and method of use thereof
|
WO2005060958A1
(en)
|
2003-12-19 |
2005-07-07 |
Kalypsys, Inc. |
(5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
|
EP1773355B1
(en)
|
2004-06-24 |
2014-06-25 |
Merck Sharp & Dohme Corp. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
US20070015771A1
(en)
|
2004-07-29 |
2007-01-18 |
Threshold Pharmaceuticals, Inc. |
Lonidamine analogs
|
BRPI0515594B8
(pt)
|
2004-09-22 |
2021-05-25 |
Janssen Pharmaceutica Nv |
compostos inibidores da interação entre mdm2 e p53,composição farmacêutica, processo para a preparação desta composição farmacêutica, usos dos compostos, suas combinações e processo para a preparação destes compostos
|
DE102004054634A1
(de)
|
2004-11-12 |
2006-05-18 |
Schwarz Pharma Ag |
Azaindolcarboxamide
|
WO2006081331A2
(en)
|
2005-01-25 |
2006-08-03 |
Prolexys Pharmaceuticals, Inc. |
Quinoxaline derivatives as antitumor agents
|
US20070161644A1
(en)
|
2005-01-25 |
2007-07-12 |
Stockwell Brent R |
Erastin analogs and uses thereof
|
US8211875B2
(en)
|
2005-02-02 |
2012-07-03 |
Nexgenix Pharmaceuticals Inc |
Local treatment of neurofibromas
|
EP1876894A1
(en)
|
2005-04-26 |
2008-01-16 |
The Board of Trustees of the University of Illinois |
Nucleoside compounds and methods of use thereof
|
MY150958A
(en)
|
2005-06-16 |
2014-03-31 |
Astrazeneca Ab |
Compounds for the treatment of multi-drug resistant bacterial infections
|
US7803828B2
(en)
|
2005-08-25 |
2010-09-28 |
Schering-Plough Corporation |
Functionally selective alpha2C adrenoreceptor agonists
|
JP2007124252A
(ja)
|
2005-10-27 |
2007-05-17 |
Sony Corp |
放送受信装置と放送受信方法およびプログラム
|
AR057960A1
(es)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
CN1923173B
(zh)
|
2006-02-24 |
2010-05-19 |
济南康泉医药科技有限公司 |
一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂
|
CN1923171B
(zh)
|
2006-02-24 |
2010-05-19 |
济南康泉医药科技有限公司 |
同载抗癌抗生素及其增效剂的复方抗癌药物缓释剂
|
EP1889847A1
(en)
|
2006-07-10 |
2008-02-20 |
DeveloGen Aktiengesellschaft |
Pyrrolopyrimidines for pharmaceutical compositions
|
WO2008021981A2
(en)
|
2006-08-09 |
2008-02-21 |
Nexgenix Pharmaceuticals, Llc. |
Local treatment of epidermal and dermal hyperproliferative lesions
|
WO2008079980A1
(en)
|
2006-12-22 |
2008-07-03 |
Alcon Research, Ltd. |
Inhibitors of protein kinase c-delta for the treatment of glaucoma
|
TW200838550A
(en)
|
2007-02-09 |
2008-10-01 |
Novartis Ag |
Organic compounds
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
WO2008127613A1
(en)
|
2007-04-11 |
2008-10-23 |
Scynexis, Inc. |
New pharmaceutical compositions
|
US20100129933A1
(en)
|
2007-04-26 |
2010-05-27 |
Forschungszentrum Karlsruhe Gmbh |
Method for detecting the binding between mdm2 and the proteasome
|
FR2921342B1
(fr)
|
2007-09-20 |
2010-03-12 |
Airbus France |
Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
|
CA2699312A1
(en)
|
2007-11-02 |
2009-05-07 |
Taiga Biotechnologies, Inc. |
Compounds for treating abnormal cellular proliferation
|
US20090318380A1
(en)
|
2007-11-20 |
2009-12-24 |
Pharmasset, Inc. |
2',4'-substituted nucleosides as antiviral agents
|
EP2219646A4
(en)
|
2007-12-21 |
2010-12-22 |
Univ Rochester |
METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
|
WO2009105234A2
(en)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
|
WO2009108551A2
(en)
|
2008-02-25 |
2009-09-03 |
H. Lundbeck A/S |
Heteroaryl amide analogues
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
WO2010015637A1
(en)
*
|
2008-08-06 |
2010-02-11 |
Novartis Ag |
New antiviral modified nucleosides
|
AR072906A1
(es)
|
2008-08-06 |
2010-09-29 |
Novartis Ag |
Nucleosidos modificados utiles como antivirales
|
US20120014911A1
(en)
|
2009-01-09 |
2012-01-19 |
Serge Fuchs |
Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor
|
US8785446B2
(en)
|
2009-01-17 |
2014-07-22 |
Children's Medical Center Corporation |
Treating post-seizure patients
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
CA2751563A1
(en)
|
2009-02-04 |
2010-08-12 |
Jelena Mann |
Methods of inhibiting fibrogenesis and treating fibrotic disease
|
JP2012517443A
(ja)
|
2009-02-06 |
2012-08-02 |
アールエフエス ファーマ,エルエルシー |
癌及びウイルス感染の治療のためのプリンヌクレオシド一リン酸プロドラッグ
|
US8475804B2
(en)
|
2009-02-20 |
2013-07-02 |
U.S. Army Medical Research And Material Command |
Compositions and methods for treatment of filovirus-mediated diseases
|
TW201107342A
(en)
|
2009-05-20 |
2011-03-01 |
Chimerix Inc |
Compounds, compositions and methods for treating viral infection
|
WO2011041385A2
(en)
|
2009-09-29 |
2011-04-07 |
Joslin Diabetes Center, Inc. |
Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
|
RS53716B1
(en)
|
2009-10-19 |
2015-04-30 |
Synta Pharmaceuticals Corp. |
COMBINED CANCER THERAPY WITH HSP90 INHIBITORS
|
WO2011057204A2
(en)
|
2009-11-06 |
2011-05-12 |
The Johns Hopkins University |
Lrrk2-mediated neuronal toxicity
|
WO2011079103A1
(en)
|
2009-12-23 |
2011-06-30 |
Sanofi |
Spiropiperidine benzylamines as beta-tryptase inhibitors
|
JP2013515724A
(ja)
|
2009-12-23 |
2013-05-09 |
サノフイ |
ベータ−トリプターゼ阻害剤としてのトロピノンベンジルアミン類
|
WO2011088137A2
(en)
|
2010-01-12 |
2011-07-21 |
H. Lee Moffitt Cancer Center & Research Institute |
Bad pathway gene signature
|
CN102191233B
(zh)
|
2010-03-04 |
2014-06-04 |
中国人民解放军军事医学科学院毒物药物研究所 |
新颖的10-23脱氧核酶类似物及其用途
|
WO2011130599A1
(en)
|
2010-04-16 |
2011-10-20 |
Enzon Pharmaceuticals, Inc. |
Polymeric conjugates of adenine nucleoside analogs
|
WO2011153553A2
(en)
|
2010-06-04 |
2011-12-08 |
The Regents Of The University Of California |
Methods and compositions for kinase inhibition
|
CN103052646A
(zh)
|
2010-07-19 |
2013-04-17 |
吉里德科学公司 |
用于制备非对映异构体纯氨基磷酸酯前药的方法
|
AR083221A1
(es)
|
2010-09-29 |
2013-02-06 |
Univ Nac Quilmes |
Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato
|
KR101817221B1
(ko)
|
2010-11-18 |
2018-01-10 |
카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 |
치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
US9085599B2
(en)
|
2011-03-16 |
2015-07-21 |
Enanta Pharmaceuticals, Inc. |
2′allene-substituted nucleoside derivatives
|
GB201107768D0
(en)
|
2011-05-10 |
2011-06-22 |
Univ Manchester |
Riboswitches
|
CN102286048A
(zh)
|
2011-06-24 |
2011-12-21 |
吉林大学 |
4-氨基-6-(3-(3-溴苯基)苯基)-5-氰基-7-(β-L-呋喃木糖)吡咯并[2, 3-d]嘧啶、同类衍生物及用于制备抗肿瘤药物
|
WO2013044030A1
(en)
|
2011-09-23 |
2013-03-28 |
Enanta Pharmaceuticals, Inc. |
2'-chloroacetylenyl substituted nucleoside derivatives
|
WO2013071415A1
(en)
|
2011-11-15 |
2013-05-23 |
University Health Network |
Targeting the rb pathway for the prevention of cancer
|
US20150057243A1
(en)
|
2012-04-02 |
2015-02-26 |
Northern University |
Compositions and Methods for the Inhibition of Methyltransferases
|
WO2014060431A1
(en)
|
2012-10-16 |
2014-04-24 |
Almirall, S.A. |
Pyrrolotriazinone derivatives as pi3k inhibitors
|
WO2014177585A2
(en)
|
2013-04-29 |
2014-11-06 |
Plasmia Biotech, S.L |
Biocatalytic production of nucleoside analogues as active pharmaceutical ingredients
|